{"schema_version":"secwatch.filing_event.v1","accession":"0000950103-25-003637","form_type":"8-K","ticker":"PGEN","cik":"0001356090","company_name":"PRECIGEN, INC.","filed_at":"2025-03-19T23:59:59+00:00","discovered_at":"2026-05-14T18:03:03.417089+00:00","generated_at":"2026-05-24T11:35:52.147954+00:00","sec_items":["2.02","9.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Precigen reports FY2024 net loss of $126M; FDA priority review for PRGN-2012 BLA","bullets":["FDA accepted BLA for PRGN-2012 with priority review; PDUFA target date Aug 27, 2025.","Pivotal study: 51% complete response (no surgeries), durable beyond 12 months (median 24 months).","FY2024 net loss $126.2M ($0.47/share) vs $95.9M in 2023; revenue down 37% to $3.9M.","Cash, equivalents, investments $97.9M; runway extended into 2026 beyond potential launch.","Raised $87.5M in Dec 2024 from convertible preferred stock ($79M) and IP/royalty sale ($8.5M)."],"urls":{"canonical":"https://secwatch.observer/filing/0000950103-25-003637","json":"https://secwatch.observer/filing/0000950103-25-003637.json","markdown":"https://secwatch.observer/filing/0000950103-25-003637.md","text":"https://secwatch.observer/filing/0000950103-25-003637.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1356090/000095010325003637/0000950103-25-003637-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1356090/000095010325003637/dp226512_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-24T11:35:52.147954+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}